Market Closed -
Nasdaq
15:59:52 2024-05-29 EDT
5-day change
1st Jan Change
63.06
USD
-0.27%
+2.27%
+14.36%
Presentation Operator MessageOperator (Operator)Good day, everyone, and welcome to today's ANI...
Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing
05-21
MT
ANI Pharmaceuticals Launches Kionex Suspension
05-20
MT
ANI Pharmaceuticals, Inc. Announces the Launch of Kionex Suspension
05-20
CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing
05-16
MT
ANI Pharmaceuticals Seeks M&A
05-10
CI
ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024
05-10
CI
Transcript : ANI Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 10, 2024
05-10
ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance
05-10
MT
Futures Rebound Pre-Bell Ahead of Earnings, Next Week's Inflation Reports; Asia, Europe Gain
05-10
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-10
CI
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue Range $520M - $542M
05-10
MT
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $4.26 - $4.67
05-10
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q1 Revenue $137.4M, vs. Street Est of $126M
05-10
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q1 EPS $1.21, vs. Street Est of $1.00
05-10
MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing
05-03
MT
Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing
04-17
MT
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension
04-09
CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,345,000, According to a Recent SEC Filing
04-03
MT
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP
03-27
CI
Capital One Initiates ANI Pharmaceuticals at Overweight Rating
03-15
MT
Ani Pharmaceuticals Insider Sold Shares Worth $671,700, According to a Recent SEC Filing
03-12
MT
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing
03-08
MT
Ani Pharmaceuticals Insider Sold Shares Worth $456,400, According to a Recent SEC Filing
03-06
MT
Ani Pharmaceuticals Insider Sold Shares Worth $330,000, According to a Recent SEC Filing
03-06
MT
Guggenheim Adjusts ANI Pharmaceuticals' Price Target to $77 From $70, Maintains Buy Rating
03-05
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
More about the company
Last Close Price
63.08
USD
Average target price
80.2
USD
Spread / Average Target
+27.14%
Consensus
1st Jan change
Capi.
+14.36% 1.22B +39.22% 731B +30.57% 586B -7.85% 348B +15.48% 319B -0.12% 273B +12.55% 235B +6.65% 202B -6.09% 203B -3.37% 158B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1